Eli Lilly and Company $LLY Stake Raised by Intech Investment Management LLC

by · The Cerbat Gem

Intech Investment Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 18.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 168,692 shares of the company’s stock after buying an additional 26,857 shares during the period. Eli Lilly and Company makes up approximately 1.2% of Intech Investment Management LLC’s portfolio, making the stock its 9th largest position. Intech Investment Management LLC’s holdings in Eli Lilly and Company were worth $131,500,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Blume Capital Management Inc. grew its holdings in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares in the last quarter. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $35,000. TD Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Finally, IMA Advisory Services Inc. purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth $55,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,024.67 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,033.62. The stock’s 50-day moving average price is $826.89 and its 200 day moving average price is $780.87. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $968.70 billion, a PE ratio of 66.97, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the company posted $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Morgan Stanley upped their price target on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a report on Thursday. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday. UBS Group increased their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $999.28.

Check Out Our Latest Stock Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).